Abstract: Subarachnoid hemorrhage (SAH) is a devastating condition that affects a total of 8 million people worldwide each year (Lauzier and Athiraman, 2024). Etiologies of SAH can be traumatic or nontraumatic, with the majority of non-traumatic SAH occurring due to intracranial aneurysm rupture (Rutledge et al., 2014). Patients with poor outcomes from SAH often survive the acute phase and go on to deteriorate in a delayed fashion from secondary brain injury induced by cascades of injury initiated by aneurysm rupture. Practice-level improvements such as dedicated neurocritical care units, rapid treatment protocols harnessing infrastructure from ischemic stroke care, and standardization of nimodipine therapy have resulted in improved outcomes for patients with SAH. Despite these advances, the morbidity of SAH remains unacceptably high, and novel therapeutic targets must be identified.